JP2012523573A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523573A5
JP2012523573A5 JP2012505086A JP2012505086A JP2012523573A5 JP 2012523573 A5 JP2012523573 A5 JP 2012523573A5 JP 2012505086 A JP2012505086 A JP 2012505086A JP 2012505086 A JP2012505086 A JP 2012505086A JP 2012523573 A5 JP2012523573 A5 JP 2012523573A5
Authority
JP
Japan
Prior art keywords
diagnostic method
disease
antibiotics
administration
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505086A
Other languages
English (en)
Japanese (ja)
Other versions
JP5650718B2 (ja
JP2012523573A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/002279 external-priority patent/WO2010118855A1/en
Publication of JP2012523573A publication Critical patent/JP2012523573A/ja
Publication of JP2012523573A5 publication Critical patent/JP2012523573A5/ja
Application granted granted Critical
Publication of JP5650718B2 publication Critical patent/JP5650718B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505086A 2009-04-14 2010-04-14 プロカルシトニンのレベルを測定することによる原発性非感染症疾患に罹患している患者における抗生物質処置のためのリスク評価 Active JP5650718B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157886 2009-04-14
EP09157886.4 2009-04-14
PCT/EP2010/002279 WO2010118855A1 (en) 2009-04-14 2010-04-14 Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

Publications (3)

Publication Number Publication Date
JP2012523573A JP2012523573A (ja) 2012-10-04
JP2012523573A5 true JP2012523573A5 (cg-RX-API-DMAC10.html) 2012-11-15
JP5650718B2 JP5650718B2 (ja) 2015-01-07

Family

ID=40886944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505086A Active JP5650718B2 (ja) 2009-04-14 2010-04-14 プロカルシトニンのレベルを測定することによる原発性非感染症疾患に罹患している患者における抗生物質処置のためのリスク評価

Country Status (15)

Country Link
US (3) US9046532B2 (cg-RX-API-DMAC10.html)
EP (1) EP2419741B1 (cg-RX-API-DMAC10.html)
JP (1) JP5650718B2 (cg-RX-API-DMAC10.html)
CN (2) CN105334330A (cg-RX-API-DMAC10.html)
CY (1) CY1122202T1 (cg-RX-API-DMAC10.html)
DK (1) DK2419741T3 (cg-RX-API-DMAC10.html)
ES (1) ES2751105T3 (cg-RX-API-DMAC10.html)
HK (1) HK1221766A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20191862T1 (cg-RX-API-DMAC10.html)
HU (1) HUE046182T2 (cg-RX-API-DMAC10.html)
LT (1) LT2419741T (cg-RX-API-DMAC10.html)
PL (1) PL2419741T3 (cg-RX-API-DMAC10.html)
PT (1) PT2419741T (cg-RX-API-DMAC10.html)
SI (1) SI2419741T1 (cg-RX-API-DMAC10.html)
WO (1) WO2010118855A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN02101A (cg-RX-API-DMAC10.html) 2012-04-12 2015-08-28 Brahms Gmbh
CN105528511A (zh) * 2014-10-25 2016-04-27 潘一琦 一种远程诊疗对比式问诊方法及其系统
CN107301319B (zh) * 2017-06-26 2021-02-26 济南市儿童医院 儿科临床及科研中抗菌药物使用危险评估系统
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
WO2019122088A1 (en) * 2017-12-20 2019-06-27 B.R.A.H.M.S Gmbh Antibiotic therapy guidance based on procalcitonin in patients with comorbidities

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
EP1110970B1 (de) * 1999-12-22 2008-05-14 Dade Behring Marburg GmbH Gegen Procalcitonin gerichtete Antikörper, ihre Herstellung und Verwendung
DE60233949D1 (de) * 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE102005034174A1 (de) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
FR2894675B1 (fr) * 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
DE102006046996A1 (de) 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
ATE533061T1 (de) 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen

Similar Documents

Publication Publication Date Title
Behr The diagnosis and treatment of idiopathic pulmonary fibrosis
Jeschke et al. Morbidity and survival probability in burn patients in modern burn care
Fan et al. Sex‐specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients
Corhay et al. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross‐sectional multicentre study
EP4184167A1 (en) Early diagnosis of infections
Shi et al. Tumour biomarkers: association with heart failure outcomes
JP7277465B2 (ja) プロカルシトニンと中間領域プロアドレノメデュリンを使用したリスク評価と患者管理のためのワークフロー
Brussino et al. Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer
Boeckmans et al. Liver stiffness as a cornerstone in heart disease risk assessment
Pan et al. Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis.
JP2007514651A5 (cg-RX-API-DMAC10.html)
Schiavetti et al. Long‐term renal function in unilateral non‐syndromic renal tumor survivors treated according to International Society of Pediatric Oncology protocols
Langsford et al. The association between biomarker profiles, etiology of chronic kidney disease, and mortality
Singh et al. Idiopathic pulmonary fibrosis: where do we stand and how far to go
JP2024009019A (ja) 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス
Wan et al. Postinfectious bronchiolitis obliterans in children
Hao et al. Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study
JP2017519008A5 (cg-RX-API-DMAC10.html)
JP5650718B2 (ja) プロカルシトニンのレベルを測定することによる原発性非感染症疾患に罹患している患者における抗生物質処置のためのリスク評価
EP3682241B1 (en) Pct and pro-adm as markers for monitoring antibiotic treatment
Ibrahim et al. COVID-19 and Liver Dysfunction
Sy‐Janairo et al. Association of metabolic‐associated fatty liver disease and risk of severe coronavirus disease 2019 illness
Park et al. Korean guidelines for diagnosis and management of interstitial lung diseases
Jiang et al. Self-reported snoring is associated with chronic kidney disease in obese but not in normal-weight Chinese adults
Shrestha et al. A study on the lipid ratios and inflammatory markers in pre-diabetic and diabetic patients